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Objective: To study the pharmacokinetic parameters of a once-daily regimen of amikacin (15 mg/kg) in association with 
other antimicrobial agents in 35 children with severe Gram-negative infections. 
Methods: A Bayesian approach was developed to optimize the amikacin regimen. The predictive performance was 
assessed by computing bias and precision. Each patient was evaluated for toxicity after 5 days of treatment. 
Results: Peak amikacin concentrations on days 2 and 5 of therapy averaged 31.3 * 9.0 mg/L and 32.4 * 7.4 mg/L, 
respectively. To achieve peak serum concentrations between 30 and 40 mg/L, individualized dosage was necessary in 
19 of 35 children. The pharmacokinetic parameters showed large interindividual variations, with a mean half-life of 2 h 
and a mean volume of distribution of 0.36 Ukg. No nephrotoxicity was observed in any of the children. After 
individualization of dosage on the basis of one measurement of peak concentration, no significant differences were 
observed between predicted and subsequently measured amikacin concentrations. 
Conclusions: Once-daily dosage of arnikacin (15 mg/kg) is well tolerated in pediatric patients; however, a loading dose 
of 20 mg/kg is recommended to achieve a therapeutic peak value between 30 and 40 mg/L. Initial serum monitoring is 
essential in a population such as children, with wide interpatient variability. Using the Bayesian approach, the amikacin 
regimen in children can then be predicted with minimal bias and good precision. 
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INTRODUCTION 
Aminoglycoside antibiotics are very important, in 
association with other antimicrobial agents, in the 
treatment of Gram-negative infections. A daily regimen 
administered in a single dose has been effective in 
several studies. Once-daily regimens of amikacin [l], 
netilmicin [2] or gentamicin [3] are less toxic than, and 
equally efficient as, more frequent administration. The 
volume of distribution is inversely correlated with age 
[4] and is greater in children than in adults [5]. This 
interpatient variation in volume of distribution has a 
direct effect on the therapeutic peak levels achieved [6]. 
Because of this wide variation in pharmacokinetic 
parameters and the low therapeutic index, amino- 
glycosides are drugs that require an individualized 
dosage. A Bayesian forecasting program has been 
described to adjust the aminoglycoside dosage [7-lo]. 
The Bayesian method is a good approach in pehatric 
patients, because few serum samples per patient are 
required to estimate the pharmacokinetic parameters 
for optimizing dosage regimens. The pharmacokinetics 
of amikacin have been documented in critically 111 [ll] 
and neutropenic children [12]. While the serum 
concentrations and the clinical efficacy of amikacin 
have been studied in children with severe Gram- 
negative infections [13,14], no information has been 
reported on amikacin pharmacokinetics in these 
patients. Therefore, the aim of this study was to 
investigate the pharmacokinetics (in terms of dosage, 
concentrations achieved and pharmacokmetic para- 
meters) and to evaluate the toxicity of a once-daily 
amikacin regimen (15 mg/kg per day) in pediatric 
patients, as well as the Bayesian forecasting method for 
predicting serum amikacin concentrations. 
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MATERIALS AND METHODS 
Patient selection 
Thirty-five children, ranging in age from 1 to 15 years, 
who were receiving amikacin for serious infection or 
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presumed infection, were included in the study. Severe 
infections were defined as follows: pyelonephritis 
(n= 12), pulmonary infection (n=4), meningitis (n=5), 
febrile syndrome in AIDS (n = 2), bacteraemia (n = l ) ,  
arthritis (n = 3), other locahzed infections (n = 8). 
Twenty-two bacterial isolates were identified as respons- 
ible: Escherichia coli(n = lo), Aeudomonus aeruginosa (n =2), 
Proteus mirabilis (n = l) ,  Staphylococcus spp. (n = 4), Neisseria 
meningitidis (n = 3), Haemophibs inzuenzae (n = 2). 
Drug administration and dosage 
Each patient received 15 mg/kg amikacin therapy at 
doses ranging &om 100 to 750 mg as a 30-min intra- 
venous infusion in 0.9% sodium chloride. Amikacin 
was given to all patients in once-daily doses combined 
with one or more other antimicrobial agents. The other 
drugs co-administered were ceftriaxone (n = 22), cefo- 
taxime (n = 7), ciprofloxacin (n = l), amoxycillin (n = 
3) ,  oxacillin (n = l), teicoplanin (n = 1) and fosfomycin 
(n = 3). For inclusion, all patients had to receive 
amikacin for a minimum of 5 days. Venous blood 
samples were collected from an indwelling catheter in 
the non-infused forearm just before infusion (trough) 
and 30 min after the end of infusion (peak). Blood 
samples for follow-up peak and trough amikacin 
concentrations were obtained at days 2 and 5. On day 
2, the amikacin dosage was adjusted to achieve a peak 
level of 230 mg/L and a trough level < 5  mg/L. On 
day 5, peak and trough samples were collected, to 
ensure that the actual levels in the serum were in fact 
close to the calculated levels. Two pairs of peak and 
trough values were required for each patient for 
inclusion in the study. Serum concentrations of 
amikacin were determined by a fluorescence polariza- 
tion immunoassay (TDx, Abbott Diagnostic Division, 
Rungis, France). The sensitivity of the assay was 0.8 
mg/L. Replicate measurements (n = 5 )  of representa- 
tive samples with concentrations in the region of 5, 10, 
20 and 35 mg/L were made in order to determine the 
mean and the standard deviation of each sample. The 
error pattern of the TDx assay for amikacin is shown 
in Figure 1. The resulting polynomial equation found 
for this assay is: 
SD (mg/L) = 0.000758C2 - 0.013354C 
+ 0.097500 
where SD represents the standard deviation of the 
measurement and C represents the measured serum 
concentration. 
Evaluation of nephrotoxicity 
The criterion of toxicity was an increase in serum 
creatinine of 15% or more between days 2 and 5 of the 
amikacin therapy. 
0 5 1 0 1 5 2 0 2 5 3 0 3 5  
Serum amikacin (rngh) 
Figure 1 
SD = standard deviation (mg/L). 
Assay error pattern of the TDx assay for amikacin. 
Bayesian forecasting of dosage 
The pharmacokinetics of amikacin were described by a 
one-compartment open model. Individual pharmaco- 
kinetic parameters were calculated according to the 
maximum Bayesian analysis a posteriori (Abbott PKS, 
Abbott Diagnostic Division, Rungis, France). The data 
required included age, gender, height, weight, serum 
creatinine, amikacin dose, dosage interval and measured 
serum concentrations. The initial population parameters 
in this model were as follows: volume of distribution 
( V d )  = 0.31 L/kg; non-renal clearance (CINR) = 
0.0417 ml/min per kg; slope of the line between 
amikacin clearance (C~T) and creatinine clearance 
(CIcreat) = 0.815. Total clearance is calculated by the 
following equation: C~T = C~NR + (slopex Clcre,,). The 
coefficients of variation were set at 30% for Vd at 25% 
for C ~ N R  and at 40% for the slope. Creatinine clearance 
was estimated by the method of Schwartz et al. [15]. 
Predictive analysis 
The predictive performance was evaluated by the 
methods described by Sheiner and Beal [16]. The pre- 
dicted amikacin serum concentrations were compared 
with those measured. Bias and precision were assessed, 
respectively, by mean prediction error (ME) with 95% 
confidence interval and root mean squared error 
(RMSE) with the corresponding equations: 
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where C,,, and C,,l,,, represent the predicted and 
measured concentrations. The bias was considered 
significantly different if the 95% confidence interval d d  
not include zero. A paired t-test between predicted and 
measured concentrations was used to evaluate their 
differences. A p-value < 0.05 was considered statistic- 
ally significant. 
RESULTS 
The demographic parameters of indvidual children, 
and the amikacin pharmacohnetic parameters are listed 
in Table 1. The half-life of amikacin ranged from 1.1 
to 4.4 h. The distribution volume of amikacin varied 
widely from patient to patient. The mean peak and 
trough amikacin serum concentrations on days 2 and 5 
are shown in Table 2. The measured serum concentra- 
tions showed large interindividual variations. O n  day 2, 
100% of the chddren had trough levels < 5 mg/L, 54% 
of which were below the limit of detection of the assay. 
O n  day 5, two children had a trough level > 5 mg/L 
(6.1 and 8.1 mg/L). To achieve therapeutic concentra- 
tions between 30 and 40 mg/L, individual dosage was 
necessary in 19 of 35 children. The dose required was 
higher than the recommended dose of 15 mg/kg, with 
a mean of 21 mg/kg. Measured and predicted serum 
amikacin concentrations at  both peak (n = 35) and 
trough (n = 35) were compared in all patients &om 
whom samples were available on day 5. The bias and 
precision of Bayesian predictive performance are shown 
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T1,2 = half-life; KI = volume of distribution; C/T = total clearance 
Bel fayo l  e t  al: Pharmacok inet ics  of  a m i k a c i n  in  p e d i a t r i c  p a t i e n t s  189  
Table 2 
concentrations (mg/L) 
Mean 5 SD trough and peak amikacin 
Day 2 Day 5 
Trough (n = 35) 1.1 ? 0.5 1.4 I 1.6 
Peak ( n  = 35) 31.3 5 9.0 32.4 1 7 . 4  
(17.1-49.6) (17.3-50.0) 
(0.8-2.4) (0.8-8.9) 
in Table 3. For both peak and trough levels, the bias is 
not significant ( p  > 0.05). Among the mean measured 
serum concentrations, the precision is greater for the 
peak (+7.06 mg/L for 32.4 2 7.4 mg/L) than for the 
trough (+1.70 mg/L for 1.4 & 1.6 mg/L). No sig- 
nificant differences were observed between measured 
and predicted trough (respectively, 1.4 4 1.6 mg/L 
and 1.2 4 0.8 mg/L) and peak (respectively, 32.4 -t 7.4 
mg/L and 33.3 & 5.4 mg/L). These data indicate that 
serum amikacin concentrations in children can be 
predicted with minimal bias and reliable precision. The 
mean length of therapy was 6 days. Nephrotoxicity 
could be evaluated in all children. No statistically 
significant difference was found in serum creatinine 
between days 2 and 5, with, respectively, 56.2 4 30.2 
pmol/L and 49.3 -t 17.2 pmol/L. No nephrotoxicity 
was observed in any of the patients. 
DISCUSSION 
The once-daily dosage regimen resulted in a higher 
peak and a lower trough level. Of the patients 46% 
and 14% had peaks of > 30 mg/L and > 40 mg/L, 
respectively, and 100% had a trough < 2.5 mg/L on 
day 2. No significant difference was noted between the 
mean peak and trough amikacin serum concentrations 
observed on days 2 and 5. There was no tendency for 
amikacin accumulation during treatment. The mean 
and individual peak amikacin levels in our study were 
lower than those previously reported in adult patients 
with severe infections [17,18] or in healthy young 
Table 3 
concentrations 
Predictive performance of serum amikacin 
MEd RMSEh 
Trough (n = 35) -0.13 +1.70 
Peak (n = 35) +1.37 +7.06 
Peak + Trough (n = 70) +0.33 +5.10 
(-0.88; +0.13) 
(-0.99; +3.73) 
(-2.02; +2.68) 
"Mean prediction error (mg/L). 
hRoot mean squared error (mg/L). 
adult volunteers (23 to 31 years) [19] receiving a 
similar dose of amikacin. These results could be 
explained by a greater volume of distribution and a 
more rapid total clearance in pediatric patients. These 
results, however, are comparable with those observed 
in critically ill patients over the age of 1 year (33.7 k 
4.8 mg/L [ l l ]  and in pediatric patients receiving 
20 mg/kg who were suffering from severe Gram- 
negative infections (36.5 4 9.1 mg/L [13]). However, 
the once-daily dosage allows the maintenance of 
higher aminoglycoside peak levels than conventional 
regimens. Moore et al. [20] demonstrated in patients 
with severe Gram-negative infections that a high peak 
concentration relative to the MIC is a major 
determinant of the clinical response to aminoglycoside 
therapy. High peak levels are effective, because the 
bactericidal activity of aminoglycosides is concentra- 
tion dependent, but the ideal therapeutic peak has not 
been defined. Beaucaire et al. [21] reported in 
critically ill adults a significantly higher mortality rate 
from infection when the first amikacin peak was below 
40 mg/L. To achieve a peak value of 40 mg/L on the 
first day of treatment, a loading dose is required, 
especially in pediatric patients with large distribution 
volume. This loading dose could correspond to 25% 
of the daily dose [22]. Indeed, in neutropenic children 
[12,23] and critically ill children [ l l ] ,  a dose of 20 
mg/kg per day has been proposed. 
We noted large interindividual variations in the 
concentrations and pharmacokinetic parameters of 
amikacin in pediatric patients. Therapeutic drug 
monitoring early in treatment is thus necessary to 
optimize dosage regimens. Predictive performance of 
the Bayesian program can be enhanced when initial 
population parameters reflect the patient population 
being monitored. In clinical routine, monitoring of 
aminoglycosides has been based on both the peak and 
trough levels. The frequency of these measurements, 
however, could be reduced to a single sampling. 
Although trough concentrations are measured to avoid 
aminoglycoside toxicity, it may be difficult to adjust 
dosage on the basis of these concentrations, which are 
currently below the limit of detection of the assay. In 
neutropenic children undergoing bone marrow trans- 
plantation receiving 20 mg/kg per day of amikacin, 
serum concentrations declined rapidly and became 
undetectable within 6 h [24]. Therefore, the serum 
peak level seems the most appropriate sample for 
monitoring. Sampling at other time intervals has been 
proposed. Blaser et al. [25] reported a significant 
correlation between nephrotoxicity and 8-h serum 
netilmicin concentrations. In comparison with serum 
gentamicin concentrations 1 h and 8 h after the initial 
administration, Bayesian analysis using the 4-h 
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concentration was the least biased and the most precise 
for predicting peak and trough concentrations [26]. 
However, these stuhes found no relationship between 
the serum concentrations and therapeutic efficacy. 
Our results regarding toxicity should be interpreted 
cautiously. Nephrotoxicity was defined as a rise of 
2 15% in serum creatinine, and no difference was noted 
between days 2 and 5 .  The higher trough concentra- 
tions observed on day 5 (6.1 and 8.9 mg/L) were not 
accompanied by an increase in serum creatinine, and 
probably reflect wide intrapatient variability in 
amikacin handling. The fiequency of nephro- and 
ototoxicity seems to be lower in children than in adults 
[24]. Other investigations to evaluate ototoxicity must 
be performed. 
In conclusion, once-daily dosage of amikacin (15 
mg/kg per day), combined with another antimicrobial 
agent, is well tolerated in pediatric patients. Serum 
concentration monitoring early in treatment is essential 
in children who show wide interpatient variability in 
pharmacokinetic parameters. Moreover, as it seems that 
the initial peak value is an important factor in clinical 
outcome, a loading dose of 20 mg/kg per day is 
recommended, in order to obtain satisfactory concen- 
trations in most children. Drug monitoring will then 
indicate whether or not dosage has to be reduced. This 
approach provides security in achieving the best results 
in children. Bayesian analysis is suitable for indi- 
vidualization of amikacin dosage for pediatric patients. 
Indeed, a single non-steady-state concentration is all 
that is required to adjust dosage early in treatment, 
preferably in the first 24 h. 
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